Jade Biosciences
Jade Biosciences is seeking a Senior Clinical Scientist to support clinical development programs in nephrology, focusing on rare or immune-mediated kidney diseases. The role involves leading Phase 2/3 studies, overseeing data review, and collaborating across cross‑functional teams while working remotely with periodic travel.
Jade Biosciences is a clinical-stage biotechnology company on a mission to transform the standard of care for patients with autoimmune diseases. The company develops a pipeline of potentially best-in-class therapies built on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Its lead candidate, JADE101, is designed to inhibit the cytokine APRIL and is being developed for the treatment of immunoglobulin A nephropathy (IgAN).
Zacks Research Downgrades Jade Biosciences (NASDAQ:JBIO) to Strong Sell
11 hours ago
Guggenheim raises Jade Biosciences stock price target on pipeline progress
1 day ago
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Jade Biosciences.
14% above the average for this role
Jade Biosciences Announces $135 Million Private Placement
Oct 7, 2025
Clinical Scientist, Neuroimmunology
AstraZeneca
Associate Director Clinical Scientist Immunology Cell Therapy
AstraZeneca
Clinical Scientist, Contractor
Aurabiosciences
Associate Director/Medical Director, Clinical Development
Climb Bio
Associate Director, Clinical Scientist
AstraZeneca
Pharma Specialist Rep (PJP) - Immuno/Nephro - QLD/NT/WA - 12 Months Max Term Contract
Roche